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Objective: To examine the epidemiology, primary care burden, and treatment of heart failure in Scotland,
UK.
Design: Cross sectional data from primary care practices participating in the Scottish continuous morbidity
recording scheme between 1 April 1999 and 31 March 2000.
Setting: 53 primary care practices (307 741 patients).
Subjects: 2186 adult patients with heart failure.
Results: The prevalence of heart failure in Scotland was 7.1 in 1000, increasing with age to 90.1 in 1000
among patients> 85 years. The incidence of heart failure was 2.0 in 1000, increasing with age to 22.4 in
1000 among patients > 85 years. For older patients, consultation rates for heart failure equalled or
exceeded those for angina and hypertension. Respiratory tract infection was the most common co-
morbidity leading to consultation. Among men, 23% were prescribed a b blocker, 11% spironolactone,
and 46% an angiotensin converting enzyme inhibitor. The corresponding figures for women were 20%
(p = 0.29 versus men), 7% (p = 0.02), and 34% (p , 0.001). Among patients , 75 years 26% were
prescribed a b blocker, 11% spironolactone, and 50% an angiotensin converting enzyme inhibitor. The
corresponding figures for patients > 75 years were 19% (p = 0.04 versus patients , 75), 7%
(p = 0.04), and 33% (p , 0.001).
Conclusions: Heart failure is a common condition, especially with advancing age. In the elderly, the
community burden of heart failure is at least as great as that of angina or hypertension. The high rate of
concomitant respiratory tract infection emphasises the need for strategies to immunise patients with heart
failure against influenza and pneumococcal infection. Drugs proven to improve survival in heart failure are
used less frequently for elderly patients and women.
T
hough heart failure is perceived to be one of the most
common, disabling, costly, and deadly cardiovascular
disorders encountered in clinical practice, its epidemiol-
ogy and the burden it places on health care systems are still
poorly defined, especially in primary care.1–3 In particular,
incidence studies are lacking. Similarly, the other problems
with which patients with heart failure consult general
practitioners have not been reported. There are also no
comparisons of the community burden of heart failure with
other common cardiovascular disorders. Lastly, there are few
contemporary data on the treatment of heart failure in
primary care across a whole country.4
The Scottish continuous morbidity recording (CMR) in
general practice scheme prospectively collects detailed infor-
mation from a number of general practices (53 at the time of
this study with 307 741 patients), broadly representative of
the whole Scottish population in terms of age, sex, socio-
economic status, and rural-urban mix.5 This scheme therefore
allows accurate estimates of the national prevalence, inci-
dence, consultation rates, concomitant medical problems,
and drug treatment for patients with heart failure in primary
care.
We have therefore used the Scottish CMR scheme to give a
more comprehensive picture of the national epidemiology
and primary care burden of heart failure than has been
obtained by existing studies.
METHODS
The CMR collects data from general practitioners in Scotland.
At the time of this study, 53 practices participated in CMR
covering 6% of the Scottish population. Any computerised
general practice can volunteer to take part in CMR. Practices
are weighted to form a national sample that is broadly
representative of the Scottish population as a whole in terms
of age, sex, deprivation, and urban–rural mix.
As previously described, general practices participating in
the CMR scheme collect data from every face to face doctor–
patient contact.5–7 All contacts with practice patients (includ-
ing temporary residents) are captured and recorded by every
doctor (including locums). Up to 10 problems can be
recorded for each contact and doctors are asked to describe
the problem as specifically in diagnostic terms as possible.
Each diagnosis is given a Read code along with an
appropriate ‘‘modifier’’ of ‘‘first’’, ‘‘recurrent’’, or ‘‘persistent’’
to denote whether the problem is new, a recurrence of a
previous problem, or a continuing problem, respectively.8 The
data are entered on to the General Practice Administration
System for Scotland computer system and an extract is sent
every month on floppy disc for analysis. The Information and
Statistics Division of the Common Services Agency of the
NHS in Scotland has a quality insurance programme for the
CMR scheme. This involves a rolling programme of practice
visits to compare CMR data with practice held records: the
completeness of contact capture was 91% and the accuracy of
Read coding was 91% in 1999/2000 (L Graham, personal
communication, 29 November 2003).
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin
receptor blocker; CMR, continuous morbidity recording; EPICA,
epidemiologia da insuficieˇncia cardiaca a aprendizagen; NHANES,
national health and nutrition examination survey; OR, odds ratio
To estimate period prevalence, all patients who had a
consultation generating a heart failure related Read code
from 1 April 1999 to 31 March 2000 were included. Any
patient who died or moved away from the practice before
31 March 2000 was excluded. Patients not attending their
general practitioner during the year of the study were also
not accounted for. While this may have led to an under-
estimate of prevalence, it is unlikely that many patients with
heart failure would not attend their general practitioner
within a 12 month period.
The incidence was estimated by including all patients with a
Read code for heart failure during the period 1 April 1999 to
31 March 2000 that had a modifier of ‘‘first’’.
The contact rate was derived from the total number of
consultations divided by attendances (‘‘contacts’’) occurring
over the year of the study.
As the CMR practices are representative of the Scottish
population, the CMR data were used to estimate prevalence,
incidence, and contact rates for the whole Scottish popula-
tion on an age and sex specific basis.
Repeat prescription data were obtained for a representative
subset of the ‘‘period prevalence’’ group, so as to describe
which medications these patients took on a regular basis.
Newly started medication (that is, where a second prescrip-
tion had not been issued) was not accounted for. The
prescription rates reported may, therefore, slightly under-
estimate the true rate of use of the drugs concerned.
Postcodes of residence were used to assign a Carstairs
deprivation category from 1 (least deprived) to 7 (most
deprived) to each person. These categories are derived from
1991 census data on the proportion of residents who are
unemployed, live in overcrowded accommodation, do not
have a car, or belong to a low occupational social class.9
For comparative purposes, contact rates for other common
cardiovascular conditions (hypertension and angina) are also
described. We examined where heart failure ranks among all
reasons for consultation with a general practitioner.10
For these analyses, the denominator was the total
registered practice population from April 1999 to March
2000 (except for prescription data, where the denominator
was the subset in which these data were available).
We compared prescribing data between men and women
and between age group categories by x2 tests. We performed
multivariate logistic regression to examine the independent
effects of age, sex, deprivation category, and general
practitioner on prescribing of heart failure medications.
RESULTS
Heart failure Read codes used
Contacts were coded as congestive heart failure (51.0%), left
ventricular failure (23.6%), heart failure—not otherwise
specified (10.0%), heart failure (6.7%), acute left ventricular
failure (4.1%), acute congestive heart failure (3.7%), chronic
congestive heart failure (1.2%), compensated cardiac failure
(0.5%), or acute heart failure (0.1%).
Prevalence of heart failure
Table 1 shows the one year CMR prevalence for men and
women of differing ages with heart failure. Prevalence was
extremely low among patients aged , 45 years, increased
sixfold between the age ranges 45–64 years and 65–74 years,
and more than doubled again between the age ranges 65–74
years and 75–84 years. The prevalence of heart failure was
higher among women (7.8/1000) than in men (6.4/1000).
Extrapolating from the CMR practices to the whole of the
country, the estimated number of Scots with heart failure in
2000 was, therefore, 37 305 (16 216 men), 87% of whom
were aged > 65 years and 60% of whom were > 75 years
(table 2).
Incidence of heart failure
Table 1 shows the one year incidence for men and women of
differing ages with heart failure. This was extremely low in
patients aged , 45 years, increased fourfold to fivefold
between the age ranges 45–64 years and 65–74 years, and
increased again twofold to threefold between the age ranges
65–74 years and 75–84 years. The incidence of heart failure
was higher among women (2.2/1000) than men (1.8/1000).
The estimated number of Scots presenting with heart failure
for the first time in the year 2000 was, therefore, 10 375
(4504 men), 84% of whom were aged > 65 years and 58% of
whom were > 75 years (table 2).
Contact rates for heart failure
The one year contact rate was extremely low among patients
aged , 45 years, increased almost sevenfold between the age
ranges 45–64 years and 65–74 years, and nearly trebled again
between the age ranges 65–74 years and 75–84 years (table 1).
The contact rate for heart failure was higher among women
(17.9/1000) than men (16.5/1000).
Overall, contact rates were approximately two to three
times higher than prevalence for both men and women. The
average number of contacts for each patient with heart
failure was 2.6 for men and 2.3 for women. The average
number of contacts for each patient doubled between the
youngest and oldest subgroups among men (from 1.4 for
patients, 45 years to 2.8 for patients> 85 years) and almost
doubled among women (1.4 v 2.5).
General practit ioner contact rates for heart failure
compared with hypertension, angina, and other
conditions
For comparison, contact rates for hypertension and angina
were 96.2 in 1000 and 21.2 in 1000, respectively, for men and
133.9 in 1000 and 19.2 in 1000, respectively, for women.
Figure 1 shows age specific contact rates for men and fig 2 for
women for hypertension, angina, and heart failure. In older
age groups, consultation rates for heart failure equalled or
exceeded those for both hypertension and, especially, angina.
Table 3 shows the most common conditions leading to
contact with a general practitioner for men and women in
different age groups. Heart failure was one of the top five
reasons for consultation for men aged > 75 years and for
women > 85 years.
Concomitant diagnoses among patients with heart
failure
Table 4 snows the top 10 concomitant diagnostic codings
among patients consulting with heart failure. For both sexes,
lower respiratory tract infection was the most common
concomitant diagnostic coding (28% of men and women).
Coronary or ischaemic heart disease was the second most
frequently coded, reported by 22% of men and 13% of
women. A concomitant coding for hypertension was recorded
for 14% of men and 16% of women, and 12% of men and 10%
of women had a coding for atrial fibrillation (atrial
fibrillation was not one of the top 10 concomitantly coded
conditions for women with heart failure). The frequency of
other diagnoses was generally similar for men and women.
Medications taken by patients with heart failure
Prescribing information was available from 22 CMR practices
with a combined list size of 140 246 patients (2.6% of the
Scottish population). The age range, sex distribution, and
level of deprivation of these patients were comparable with
those of the total Scottish population. Tables 5, 6, and 7 show
the medications prescribed for patients with heart failure,
stratified by sex and age. Diuretics were prescribed for 81%
of these patients, angiotensin converting enzyme (ACE)
inhibitors for 39%, b blockers for 21%, digoxin for 21%, and
spironolactone for 9%. Only 11% of these patients were
prescribed both an ACE inhibitor and a b blocker, and 1%
were prescribed the combination of ACE inhibitor, b blocker,
and spironolactone.
There were significant sex differences in prescribing.
Eighty per cent of men were prescribed a diuretic, 46% an
ACE inhibitor, 23% a b blocker, 11% spironolactone, and 24%
digoxin. The corresponding figures for women were 81%
(p = 0.87 v men), 34% (p , 0.001), 20% (p = 0.29), 7%
(p = 0.02), and 18% (p = 0.02), respectively. There were
also significant age differences, with 50% of patients , 75
years, but only 33% of patients > 75, prescribed an ACE
inhibitor (p , 0.001). Twenty six per cent of patients , 75
years and 19% of patients > 75 years were prescribed a
b blocker (p = 0.04). These proportions for spironolactone
were 11% and 7%, respectively (p = 0.04). There was no
difference in the rate of use of digoxin.
There was a clear association between age and sex (more
older patients were women) and multivariate analyses
showed that age was the most important factor influencing
prescribing patterns. Indeed, sex was only significantly
associated with ACE inhibitor prescribing (men were 42%
more likely (p = 0.009) to be prescribed an ACE inhibitor
Table 1 Contact rates, incidence, and prevalence per 1000 population by sex and age group for all CMR practices in
















Men 45–64 37990 163 4.3 52 1.4 378 9.9
65–74 11446 294 25.7 69 6.0 745 65.1
75–84 5802 371 63.9 117 20.2 994 171.3
>85 1290 134 103.9 32 24.8 372 288.4
>65 18538 799 43.1 218 11.8 2111 113.9
>75 7092 505 71.2 149 21.0 1366 192.6
All ages 152033 973 6.4 271 1.8 2504 16.5
Women 45–64 37356 120 3.2 48 1.3 247 6.6
65–74 13428 278 20.7 82 6.1 587 43.7
75–84 9408 500 53.1 127 13.5 1174 124.8
>85 3617 308 85.2 78 21.6 763 210.9
>65 26453 1086 41.1 287 10.9 2524 95.4
>75 13025 808 62.0 205 15.7 1937 148.7
All ages 155708 1213 7.8 338 2.2 2,781 17.9
Both sexes 45–64 75346 283 3.8 100 1.3 625 8.3
65–74 24874 572 23.0 151 6.1 1332 53.5
75–84 15210 871 57.3 244 16.0 2168 142.5
>85 4907 442 90.1 110 22.4 1135 231.3
>65 44991 1885 41.9 505 11.2 4635 103.0
>75 20117 1313 65.3 354 17.6 3303 164.2
All ages 307741 2186 7.1 609 2.0 5285 17.2
CMR, continuous morbidity recording; HF, heart failure.
There were 18 patients (11 men) aged(44 years with heart failure, four with a first diagnosis (one man). These patients made 25 contacts (15 men). The CMR
practice population ,45 years is 187404 (95505 men).
Table 2 Estimated number of contacts, first diagnoses, and patients by sex and age group and percentages of totals for















Men 0–44 183 1.1 17 0.4 249 0.6
45–64 2510 15.5 801 17.8 5820 13.9
65–74 5041 31.1 1183 26.3 12775 30.6
75–84 6238 38.5 1967 43.7 16713 40.0
>85 2244 13.8 536 11.9 6231 14.9
>65 13523 83.4 3686 81.8 35719 85.5
>75 8482 52.3 2503 55.6 22944 54.9
All ages 16216 NA 4504 NA 41788 NA
Women 0–44 118 0.6 51 0.9 168 0.3
45–64 1979 9.4 792 13.5 4073 8.4
65–74 5046 23.9 1489 25.4 10656 22.1
75–84 8743 41.5 2221 37.8 20529 42.5
>85 5203 24.7 1318 22.4 12888 26.7
>65 18992 90.1 5028 85.6 44073 91.2
>75 13946 66.1 3539 60.3 33417 69.2
All ages 21089 NA 5871 NA 48314 NA
Both sexes 0–44 301 0.8 68 0.7 417 0.5
45–64 4489 12.0 1593 15.4 9893 11.0
65–74 10087 27.0 2672 25.8 23431 26.0
75–84 37242 41.3 4188 40.4 37242 41.3
>85 7447 20.0 1854 17.9 19119 21.2
>65 32515 87.2 8714 84.0 79792 88.6
>75 22428 60.1 6042 58.2 56361 62.6
All ages 37305 NA 10375 NA 90102 NA
HF, heart failure; NA, not applicable.
*CMR age and sex specific rates extrapolated to whole of Scotland.
than women, even after adjusting for age). The multivariate
analyses showed that, compared with patients , 65 years,
older patients were less likely to be prescribed ACE inhibitors
(odds ratio (OR) 0.60 for patients aged 75–84 years
(p , 0.001) and OR 0.39 for patients > 85 years
(p , 0.001)) or the combination of ACE inhibitors plus b
blockers (OR 0.60 for patients aged 75–84 years (p = 0.03)
and OR 0.32 for patients > 85 years (p = 0.001)).
DISCUSSION
This study has a number of important strengths. Not only
does it describe the prevalence and incidence of heart failure
across a whole country but it also describes overall contact
rates with general practitioners. Furthermore, we report
comparative contact rates for other common cardiovascular
(and non-cardiovascular) conditions. Finally, we also
describe the contemporary pharmacological treatment of
heart failure in primary care.
A number of recent prevalence studies in the UK have
focused on the presence of echocardiographic left ventricular
systolic dysfunction and not a clinical diagnosis of heart
failure per se.11–13 The first of these, from Glasgow, was
limited in concentrating on a relatively young age group
(1640 patients aged 45–74), when heart failure is known to
be uncommon before the age of 70 years (as confirmed in the
present study).11 The second report from Poole in England
examined 817 patients aged 70–84 years.12 Another more
recent survey examined 3960 patients > 45 years, but, like
the former studies, was limited to a single urban area (the
West Midlands of England).13 Other studies in the UK have
usually involved only a small number (one to three) of
general practices or relied on diuretic prescription as a sur-
rogate for heart failure.14–17 Recording of concomitant medical
problems, concomitant drug treatment, and the frequency
and nature of contacts (surgery or office visits, home visits,
out of hours visits) has been limited or absent.14–17
Figure 1 Age stratified general
practitioner consultation rates per 1000
population for heart failure, angina,
and hypertension for men.
Figure 2 Age stratified general
practitioner consultation rates per 1000
population for heart failure, angina,
and hypertension for women.
It is difficult to precisely compare our findings with prior
studies, as many of these did not include both sexes or the
whole population age range. Nevertheless, with respect to
men aged 0–74 years, our prevalence (0.32%) was very close
to that found in the Rochester epidemiology project
(0.33%).18 19 The proportions for women were 0.28% in
Scotland and 0.21% in Rochester. The NHANES (national
health and nutrition examination survey) investigators
reported a prevalence of 1.1% among men and 1.0% among
women aged 25–74 years in the USA.20 Our prevalence among
men aged 45–74 years was 0.92% and 0.78% among women.
We also had reasonably close agreement with another north
European study, the Rotterdam study, which reported a
prevalence of 3.4% in patients aged 65–84 years21 (compared
with 3.6% in the same age group in our study). On the other
hand, a study from Copenhagen reported that the prevalence
of heart failure signs and symptoms in three general practices
was 6.4% among patients . 50 years. This is much higher
than the prevalence in our study (1.8% among patients . 45
years).22
Another national primary care survey from southern
Europe also reported discrepant findings. The EPICA (epide-
miologia da insuficieˇncia cardiaca a aprendizagen) investi-
gators reported a prevalence of heart failure among men aged
. 25 years of 4.33%. The prevalence among women was
4.38%.23
The deficiencies in existing epidemiological investigations
of heart failure are even more apparent when it comes to
incidence studies, with only one Finnish, two UK, and one
US study reported until recently.24–28 The Finnish and
American studies were confined to a limited geographical
area (four rural communities in eastern Finland and Olmsted
County in Minnesota).24–26 Of the two UK studies, one was
hospital based, was limited to part of London, and adopted
an unusually broad definition of heart failure (including
heart failure arising as a complication during hospitalisation
with an acute coronary syndrome).27 The second study used
data from the UK general practice research database to
describe the incidence of newly diagnosed heart failure
during 1996.28 That study did not, however, describe
pharmacological treatment.
The incidence of heart failure in the Scottish population
was 1.8 in 1000 in men and 2.2 in 1000 in women, and this
figure is in keeping with the previous estimates from the UK
(1.4 and 1.2/1000),27 Finland (1.0 and 4.0/1000),24 and the
USA (3.4 and 2.4/1000).26
What appears to be different, at first sight, between the
prior studies and ours is the higher overall prevalence and
incidence of heart failure among women than among men.
This, however, reflects the wider age range included in our
study, compared with most others, and the predominance of
women over men with heart failure in the very elderly
segment of the population.29 30
The lack of information on contact rates in primary care
has been a surprising gap in the literature on heart failure.31
We found that the contact rate is two to three times the
Table 3 The five most common reasons for consulting a general practitioner in Scotland by sex and age group in 2000*
Men Women
45–64 years 65–74 years 75–84 years >85 years 45–64 years 65–74 years 75–84 years >85 years
Hypertension 1 (229) 1 (445) 1 (386) 4 (155) 3 (269) 1 (572) 1 (565) 1 (242)
Back problems 2 (148) NA NA NA 4 (177) 3 (150) 4 (169) NA
Depression 3 (125) NA NA NA 2 (275) 4 (148) NA NA
Lower RTI 4 (88) 2 (175) 2 (216) 1 (290) NA 2 (189) 2 (216) 2 (240)
Anxiety 5 (73) NA NA NA 5 (160) NA NA NA
Coronary heart disease NA 3 (156) 5 (125) NA NA NA NA NA
COPD NA 4 (147) 3 (198) 3 (160) NA NA NA NA
Diabetes mellitus NA 5 (143) NA NA NA NA NA NA
Heart failure NA NA 4 (136) 2 (248) NA NA NA 5 (169)
Menopause NA NA NA NA 1 (313) NA NA NA
Osteoarthritis NA NA NA NA NA 5 (143) 3 (186) NA
Urinary tract infection NA NA NA NA NA NA 5 (147) NA
Dementia NA NA NA NA NA NA NA 3 (215)
General miscellaneous NA NA NA 5 (154) NA NA NA 4 (185)
Rank (1–5) and consultation rate per 1000 population (brackets).
COPD, chronic obstructive pulmonary disease; NA, not applicable; RTI, respiratory tract infection.
*Year ending December 2000.
Table 4 Proportion of patients with HF seen with a specified condition or illness, April
1999–March 2000*
Condition/illness Men (n = 973) Women (n = 1213)
Lower RTI 273 (28.1%) 338 (27.9%)
Coronary heart disease—miscellaneous 216 (22.2%) 159 (13.1%)
Breathlessness 201 (20.7%) 247 (20.4%)
Angina 144 (14.8%) 141 (11.6%)
COPD 142 (14.6%) NA
Upper RTI (excluding sore throat) 141 (14.5%) 176 (14.5%)
Hypertension 134 (13.8%) 196 (16.2%)
Atrial flutter/fibrillation 114 (11.7%) NA
Oedema 111 (11.4%) 177 (14.6%)
Miscellaneous 108 (11.1%) 144 (11.9%)
Back problems NA 153 (12.6%)
Osteoarthritis NA 143 (11.8%)
*Number (per cent).
NA, not applicable.
prevalence—that is, patients average two to three heart
failure related contacts each year with their general practi-
tioner. This rate was remarkably consistent between men and
women and across all age groups.
Not only are there few data on the rates of consultation
with general practitioners but there is also little information
on the reasons for consultation.32 33 We found that lower
respiratory tract infection was the single most common
problem recorded by general practitioners for both men and
women with heart failure. The potential importance of this is
suggested by the knowledge that pulmonary infection is a
commonly recorded precipitant of heart failure hospitalisa-
tion.34 35 These two observations underscore the importance
of influenza and pneumococcal immunisations for patients
with heart failure.36 37 The other major co-morbidities reflect
the most common causes of heart failure (coronary artery
disease and hypertension), other smoking related ill-
nesses (such as chronic obstructive pulmonary disease),
and degenerative diseases of aging (back problems, osteo-
arthritis).
Another gap in our knowledge has been how the pri-
mary care burden of heart failure compares with that of
other cardiovascular and non-cardiovascular conditions.32 33
Consultation rates for heart failure were much lower than
those for angina and, especially, hypertension for patients
, 75 years. Thereafter, heart failure consultation rates
exceeded those for angina and by the age of > 85 exceeded
those for hypertension also. It is interesting to speculate that
the falling prevalence and consultation rates for hypertension
and angina, relative to heart failure, in the older age groups
may reflect the natural history of coronary heart disease and
hypertension progressing to heart failure over time.
Another important feature of this study is the description
of the contemporary pharmacological management of heart
failure in primary care across a whole country. Though, as
expected, most patients had been prescribed a diuretic, there
was a striking age differential in the prescription of evidenced
based treatments: older patients were significantly less likely
to be prescribed ACE inhibitors, b blockers, or spironolactone.
There are several possible explanations for these observa-
tions. The above treatments are indicated when left
ventricular systolic function is reduced and not when it is
preserved. Heart failure in the elderly is more often associated
with preserved left ventricular systolic function.30 Digoxin,
however, was used at least as commonly in the elderly, yet is
also indicated only when left ventricular systolic function is




45–64 65–74 75–84 >85 ,75 >75 All ages
Number 64 132 164 74 201 238 439
Furosemide 36 80 114 49 119 163 282
(56.3%) (60.3%) (69.5%) (66.2%) (59.2%) (68.5%) (64.2%)
Any diuretic 47 105 139 58 155 197 352
(73.4%) (79.6%) (84.8%) (78.4%) (77.1%) (82.8%) (80.2%)
ACE inhibitor 39 71 69 21 111 90 201
(60.9%) (53.8%) (42.1%) (28.4%) (55.2%) (37.8%) (45.8%)
ARB 4 5 8 1 9 9 18
(6.3%) (3.8%) (4.9%) (1.4%) (4.5%) (3.8%) (4.1%)
b Blocker 20 34 33 14 55 47 102
(31.3%) (25.8%) (20.1%) (18.9%) (27.4%) (19.8%) (23.2%)
Spironolactone 12 16 16 4 28 20 48
(18.8%) (12.1%) (9.8%) (5.4%) (13.9%) (8.4%) (10.9%)
Digoxin 17 30 43 15 47 58 105
(26.6%) (22.7%) (26.2%) (20.3%) (23.4%) (24.4%) (23.9%)
Any HF treatment 57 114 149 61 175 210 385
(89.1%) (86.4%) (90.9%) (82.4%) (87.1%) (88.2%) (87.7%)
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.




45–64 65–74 75–84 .85 ,75 >75 All ages
Number 56 116 227 166 176 393 569
Furosemide 30 66 124 97 97 221 318
(53.6%) (56.9%) (54.6%) (58.4%) (55.1%) (56.2%) (55.9%)
Any diuretic 42 95 190 132 138 322 460
(75.0%) (81.9%) (83.7%) (79.5%) (78.4%) (81.9%) (80.8%)
ACE inhibitor 24 53 76 41 77 117 194
(42.9%) (45.7%) (33.5%) (24.7%) (43.8%) (29.8%) (34.1%)
ARB 5 5 14 6 10 20 30
(8.9%) (4.3%) (6.2%) (3.6%) (5.7%) (5.1%) (5.3%)
b Blocker 14 27 51 22 41 73 114
(25.0%) (23.3%) (22.5%) (13.3%) (23.3%) (18.6%) (20.0%)
Spironolactone 3 10 13 12 13 25 38
(5.4%) (8.6%) (5.7%) (7.2%) (7.4%) (6.4%) (6.7%)
Digoxin 6 18 43 35 25 78 103
(10.7%) (15.5%) (18.9%) (21.1%) (14.2%) (19.8%) (18.1%)
Any HF treatment 49 102 206 139 153 345 498
(87.5%) (87.9%) (90.7%) (83.7%) (86.9%) (87.8%) (87.5%)
reduced. Perhaps ACE inhibitors, b blockers, and spirono-
lactone have a perceived or real contraindication more often
among the elderly or are not as well tolerated by the elderly.30
The other possibility is that these treatments are not offered
to the elderly as often as they are to younger patients, as has
been reported for other conditions.38 The concern that older
patients with heart failure may be inappropriately denied
treatments proven to reduce morbidity and mortality is
worthy of further investigation. Women also received less
evidence based treatment and this was not wholly explained
by the generally older average age of women. Preserved left
ventricular systolic function is also more common among
women and this may explain at least part of the sex
difference in treatment.29 30 Women may also tolerate these
other treatments less well and there is some evidence that
this is true for ACE inhibitors.29 39 Curiously, however, the
greatest sex difference in evidence based prescribing was for
spironolactone, which should be better tolerated by women
than men. This again raises the concern, as in other disease
areas, that women are undertreated compared with men.40
As in any study of this type, there are limitations. One is
the lack of information on cardiac structure and function,
which did not allow us to differentiate between patients with
reduced and preserved left ventricular systolic function.
Nevertheless, we have been able to provide information on
the community burden of the syndrome of heart failure,
rather than left ventricular systolic dysfunction, which has
been the main focus of most other epidemiological studies.
Secondly, we do not have any independent confirmation of
heart failure diagnoses or data on disease severity.
In summary, this study confirms that heart failure is
predominantly a problem of the elderly. When the full age
spectrum is accounted for, there are more women than men
with heart failure in the population. In the elderly, heart
failure is one of the most common causes of consultation
with a general practitioner and is at least as common a cause
of consultation as angina and hypertension. Patients consult
on average two to three times a year. Respiratory tract
infection is the most common co-morbidity leading to
consultation in primary care. There is a notable age
discrepancy in prescribing of evidence based treatment, with
the elderly receiving less life saving treatment. There is also
an independent sex effect with women also receiving less
evidence based treatment. These discrepancies merit further
investigation.
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